Cambridge Open Engage home
What is Cambridge Open Engage?
How to Submit
Browse
About
News [opens in a new tab]

Coronavirus canSAR – a Data-Driven, AI-Enabled, Drug Discovery Resource for the Research Community

07 August 2020, Version 1

Abstract

We describe an AI-enabled, integrated Coronavirus drug discovery knowledgebase, free for the research community. Its goal is to make accessible up to date information relevant to drug discovery for SARS-CoV-2 and other coronaviruses. It builds on great knowledge from across therapeutic areas and provides unbiased, systematic, objective information to empower the international effort.

Keywords

coronavirus
drug discovery
knowledgebase
SARS-CoV-2
COVID-19

Supplementary weblinks

Title
Description
Actions
Title
Description
Actions
View

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.

Version History

Aug 07, 2020 Version 1

Metrics

4,016
566
2
Views
Downloads

License

CC logo
CC
BY logo
BY
NC logo
NC
ND logo
ND
The content is available under CC BY NC ND 4.0 [opens in a new tab]

DOI

10.26434/chemrxiv.12286877.v1
D O I: 10.26434/chemrxiv.12286877.v1 [opens in a new tab]

Funding

Cancer Research UK (C35696/A23187)
Wellcome Trust (WT212969/Z/18/Z)
Wellcome Trust (WT204735/Z/16/Z)

Author’s competing interest statement

CM, AAA, EVF, PdM, ILM, JET, KHC, JC, DS, IC, PW and BAL are employees of the Institute of Cancer Research (ICR) which has a commercial interest in a range of drug targets. The ICR operates a Rewards to Inventors scheme through which employees of the ICR may receive financial benefit following commercial licensing. PW is a former employee of AstraZeneca and received research funding from Vernalis, Astex, AstraZeneca, BACIT and Sixth Element Capital/CRT Pioneer Fund. PW is a consultant/scientific advisory board member for NextechInvest, Storm Therapeutics, Astex Pharmaceuticals and CV6, and holds stock in Chroma Therapeutics, NextInvest and Storm Therapeutics. He is also a Non-Executive Director of Storm Therapeutics and the Royal Marsden NHS Trust and a Board Director of the nonprofit Chemical Probes Portal. BAL is currently or has been a consultant to Astex Pharmaceuticals, GSK, Astelas Pharma and Difiniens AG (member of Astra Zeneca group). BAL is a former employee of Inpharmatica Ltd. IC is currently or has been a consultant to Epidarex LLP, AdoRx Therapeutics and Enterprise Therapeutics, has received research funding from Astex, Merck KGaA, Janssen Biopharma, Monte Rosa Therapeutics and Sixth Element Capital/CRT Pioneer Fund, and holds stock in Monte Rosa Therapeutics AG. IC is a former employee of Merck Sharp & Dohme.

Share